Invention in the REGENERATIVE MEDICINE is what we do every day, benefits of patients is our final goal

Our Products

Home > Products

Cata #: Name of Product: Price:
HTF-2096 Recombinant Human Runx3-11R Protein $300

Recombinant Human Runx3-11R Protein

Product Name: Recombinant Human Runx3-11R Protein
Catalog #:  HTF-2096
Manufacture:  LD Biopharma, Inc.

Human runt-related transcription factor 3 (Runx3) gene encodes a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence 5'-PYGPYGGT-3' found in a number of enhancers and promoters, and can either activate or suppress transcription. It also interacts with other transcription factors. It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. Recent data indicated that Runx3 can mediate TCF7 repression, which coordinately enforce acquisition of CT8+ TEFF (CT8 cytotoxic cell) functions and protect the cytotoxic lineage integrity by preventing TFH-lineage deviation.

Full-length human Runx3 cDNA (428aa, Isoform-I, BC013362) was constructed with codon optimization using gene synthesis technology and expressed with a small T7-His-TEV cleavage site Tag (29aa) fusion at its N-terminal and 11 arginine (11R tag) at its C-terminal. This Rnux3-11R fusion protein. It was expressed in E.coli as inclusion bodies. The final product was refolded using our unique “temperature shift inclusion body refolding” technology and chromatographically purified.

Gene Symbol:  Runx3 (AML2; CBFA3; PEBP2aC) 
Accession Number:  NP_001026850
Species:  Human
Package Size:  20 µg / Vial   
Composition: 0.2 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, Sucrose and DTT.
Storage: In Liquid. Keep at -80°C for long term storage. Product is stable at 4 °C for at least 30 days.
Key Reference: J.Justin Milner, et al., Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours. Nature doi: 10.1038/nature24993. (2017)
Selvarajan V, et al., RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC. Leukemia 31 (10), 2219-2227 (2017)
Morita K, et al., Genetic regulation of the RUNX transcription factor family has antitumor effects. J. Clin. Invest. 127 (7), 2815-2828 (2017)
Saikia S, et al., Alteration in the expression of MGMT and RUNX3 due to non-CpG promoter methylation and their correlation with different risk factors in esophageal cancer patients. Tumour Biol. 39 (5), 1010428317701630 (2017)

1. May be used for in vitro Runx3 mediated gene transcription regulation study of CD8+ T cell non-lymphoid or tumor tissue migration controlling by intracellular delivery of this protein.

2. May be used for mapping protein-protein interaction.

3. May be used as specific substrate protein for kinase, and ubiquitin (Sumo pathway) related enzyme functional screening assays.

4. Potential biomarker/therapeutic protein for cancer immune-therapy, such as regulating CD8 T cell tumor infiltration.

5. As immunogen for specific antibody production.

Quality Control: Purity: > 90% by SDS-PAGE.
Download Datasheet